Superworth

Sutro Biopharma profit margin STRO

Gross, operating and net profit as a share of revenue over the last twelve months, from 2017.

Net margin, 12 months
n/m
not a meaningful number
Peer median
10.6%

Sutro Biopharma's net margin works out at −395% over the last twelve months, but it is not a meaningful number: a margin outside minus 100% to 100% is moved by items that are not sales.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY2025n/an/a
FY2024n/an/a
FY2023−69.5%−58.1%
FY2022n/an/a
FY2021n/an/a
FY2020−75.2%n/a
FY2019n/an/a
FY2018−91.9%−96.9%
FY2017−38.1%n/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26n/an/an/a
Q1 FY26n/an/an/a
Q4 FY25n/an/an/a
Q3 FY25n/an/an/a
Q2 FY25n/an/an/a
Q1 FY25n/an/an/a
Q4 FY24n/an/an/a
Q3 FY24−77.0%n/a−80.8%
Q2 FY24−73.5%n/a−62.7%
Q1 FY24−74.6%n/a−67.3%
Q4 FY23−69.5%n/a−58.1%
Q3 FY23n/an/an/a

Against its peers

Companies in Healthcare nearest Sutro Biopharma's size, closest first, today.

CompanyProfit margin
STROSutro Biopharman/m
PDEXPro DEX17.6%
PLXProtalix BioTherapeutics23.5%
NATRNatures Sunshine Products3.7%
ELMDElectromed15.3%
UTMDUtah Medical Products29.0%
KEQUKewaunee Scientific3.0%
ICCCImmucell2.6%
INFUInfuSystem6.0%
LFVNLifevantage2.8%
SPROSpero Therapeutics15.7%
Peer median10.6%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Sutro Biopharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.